Astria Q3 2023 Corporate Update November 13, 2023 Forward Looking Statements This press release contains forward-looking statements within the meaning of applicable securities laws and regulations including, but not limited to, statements regarding: our expectations regarding the potential significance of the results from the Phase 1a clinical trial of STAR-0215; our expectations regarding the timing, nature, goals and results of our Phase 1b/2 ALPHA-STAR clinical trial of STAR-0215, including the expected ...

Financial Performance - Total current assets decreased from $227,690 thousand as of December 31, 2022, to $191,466 thousand as of September 30, 2023, a decline of approximately 15.9%[17] - The net loss for the three months ended September 30, 2023, was $17,727 thousand, compared to a net loss of $11,997 thousand for the same period in 2022, reflecting a 47.2% increase in losses[22] - The net loss for the nine months ended September 30, 2023, was $41.481 million, compared to a net loss of $38.571 million for the same period in 2022[31] - The company reported a total comprehensive loss of $17,727 thousand for the three months ended September 30, 2023, compared to a comprehensive loss of $12,026 thousand for the same period in 2022[22] - The company reported net cash used in operating activities of $38.207 million for the nine months ended September 30, 2023, compared to $32.869 million for the same period in 2022[31] Cash and Liquidity - Cash and cash equivalents increased significantly from $20,525 thousand to $119,806 thousand, representing a growth of 482.5%[17] - As of September 30, 2023, cash and cash equivalents totaled $119.8 million, a significant increase from $46.0 million on September 30, 2022, representing a growth of 159%[48] - As of September 30, 2023, the company had $188.8 million in available cash, cash equivalents, and short-term investments, estimated to sustain operations for at least twelve months[36] - The company raised an additional $64.0 million in gross proceeds from the October 2023 Financing, enhancing its liquidity position[122] Operating Expenses - Total operating expenses for the three months ended September 30, 2023, were $20,236 thousand, up 63.2% from $12,386 thousand for the same period in 2022[20] - Research and development expenses rose to $13,338 thousand for the three months ended September 30, 2023, compared to $7,698 thousand in the prior year, an increase of 73.5%[20] - General and administrative expenses rose by 47% to $6.9 million for the three months ended September 30, 2023, up from $4.7 million in the prior year[116] - Total operating expenses for the nine months ended September 30, 2023, were $48.8 million, a 25% increase from $39.2 million in the same period of 2022[118] Equity and Liabilities - Total liabilities decreased slightly from $9,417 thousand as of December 31, 2022, to $9,382 thousand as of September 30, 2023[17] - Stockholders' equity decreased from $221,216 thousand as of December 31, 2022, to $184,479 thousand as of September 30, 2023, a decline of approximately 16.6%[17] - The company had an accumulated deficit of $549.1 million as of September 30, 2023[36] Research and Development - The company’s lead product candidate, STAR-0215, is in clinical development for the treatment of hereditary angioedema[34] - STAR-0215 received FDA Fast Track designation in July 2023, indicating its potential as a first-choice preventative treatment for hereditary angioedema[86] - The company plans to submit an IND for STAR-0310 by the end of 2024 and initiate a Phase 1a clinical trial in Q1 2025[96] - Research and development expenses for STAR-0215 were $18.3 million for the nine months ended September 30, 2023, compared to $14.6 million for the same period in 2022[106] Future Outlook and Risks - The company anticipates continuing to incur significant operating losses for the next several years as it develops its product candidates[37] - Future funding requirements will depend on the progress and costs of clinical trials for STAR-0215 and STAR-0310, as well as the ability to establish collaborations and licensing arrangements[140] - The company acknowledges the uncertainty in generating substantial product revenues and may need to rely on additional financing to achieve business objectives[141] - The company’s future commercialization efforts may be delayed or limited if additional funds are not raised when needed[143]

[PART I. FINANCIAL INFORMATION](index=3&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) This section presents Astria Therapeutics' unaudited condensed consolidated financial statements, including balance sheets, statements of operations, comprehensive loss, changes in stockholders' equity, cash flows, and related notes for the periods ended June 30, 2023 [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2023, total assets decreased to **$207.1 million** from **$230.6 million** at year-end 2022, driven by reduced short-term investments, while total liabilities and stockholders' equity also decreased Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2023 | December 31, 2022 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $133,958 | $20,525 | | Short-term investments | $69,000 | $205,912 | | **Total Assets** | **$207,053** | **$230,633** | | **Liabilities & Equity** | | | | Total current liabilities | $6,598 | $9,060 | | **Total Liabilities** | **$6,651** | **$9,417** | | **Total Stockholders' Equity** | **$200,402** | **$221,216** | [Condensed Consolidated Statements of Operations](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) The company reported a **net loss of $12.6 million** for Q2 2023, an increase from the prior year, while the six-month net loss decreased to **$23.8 million** due to higher other income Statement of Operations Summary (in thousands, except per share data) | Metric | Three Months Ended June 30, 2023 | Three Months Ended June 30, 2022 | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 | | :--- | :--- | :--- | :--- | :--- | | Research and development | $9,089 | $6,617 | $17,122 | $16,975 | | General and administrative | $6,013 | $4,832 | $11,473 | $9,852 | | **Loss from operations** | **($15,102)** | **($11,449)** | **($28,595)** | **($26,827)** | | Total other income, net | $2,536 | $199 | $4,841 | $253 | | **Net loss** | **($12,566)** | **($11,250)** | **($23,754)** | **($26,574)** | | Net loss per share | ($0.45) | ($0.86) | ($0.85) | ($2.04) | [Condensed Consolidated Statements of Cash Flows](index=10&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities was **$23.9 million** for the six months ended June 30, 2023, offset by **$137.1 million** from investing activities, resulting in a **$113.4 million** net increase in cash Cash Flow Summary for the Six Months Ended June 30 (in thousands) | Activity | 2023 | 2022 | | :--- | :--- | :--- | | Net cash used in operating activities | ($23,949) | ($22,620) | | Net cash provided by (used in) investing activities | $137,072 | ($33,899) | | Net cash provided by financing activities | $310 | $0 | | **Net increase (decrease) in cash** | **$113,433** | **($56,519)** | [Notes to Condensed Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) These notes detail the company's biopharmaceutical focus on rare diseases, particularly **STAR-0215** for HAE, and confirm **$203.0 million** in cash and investments are sufficient for at least twelve months of operations - The company is a biopharmaceutical firm focused on developing novel therapeutics for rare and niche allergic and immunological diseases, with its lead product candidate, **STAR-0215**, in clinical development for **hereditary angioedema (HAE)**[29](index=29&type=chunk) - As of June 30, 2023, the company had **$203.0 million** in cash, cash equivalents, and short-term investments, which management estimates is sufficient to sustain operations for at least twelve months from the financial statement issuance date[31](index=31&type=chunk) - The company maintains an at-the-market (ATM) offering program with Jefferies, with **$50.0 million** of common stock available for sale as of June 30, 2023; no sales were made under this program during the first six months of 2023[30](index=30&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=19&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial condition and operations, highlighting **STAR-0215** clinical progress, increased operating expenses, and liquidity, with cash expected to fund operations through the **first half of 2025** [Overview](index=19&type=section&id=Overview) Astria Therapeutics focuses on rare allergic and immunological diseases, with **STAR-0215** as its lead candidate for HAE, having completed Phase 1a and initiated the Phase 1b/2 ALPHA-STAR trial - The company's lead product candidate is **STAR-0215**, a monoclonal antibody inhibitor of plasma kallikrein for the treatment of **hereditary angioedema (HAE)**[78](index=78&type=chunk) - The vision for **STAR-0215** is to become the first-choice preventative **HAE treatment** with administration every three or six months, aiming to normalize patients' lives[79](index=79&type=chunk) - The company initiated the **Phase 1b/2 ALPHA-STAR trial** in February 2023 and expects initial data from single and multiple dose cohorts in **mid-2024**; a long-term open-label trial, **ALPHA-SOLAR**, is planned to start in **Q4 2023**[81](index=81&type=chunk)[83](index=83&type=chunk) [Results of Operations](index=22&type=section&id=Results%20of%20Operations) Q2 2023 R&D expenses increased **37% to $9.1 million** and G&A expenses rose **24% to $6.0 million**, while other income significantly increased due to financing proceeds - Research and development expenses for Q2 2023 **increased by $2.5 million (37%)** year-over-year, primarily due to the advancement of the **STAR-0215 program** into two clinical trials (Phase 1a and Phase 1b/2)[101](index=101&type=chunk) - General and administrative expenses for Q2 2023 **increased by $1.2 million (24%)** year-over-year, mainly due to higher professional services and employee-related costs to support clinical trial initiation and company growth[102](index=102&type=chunk)[103](index=103&type=chunk) - Other income, net, **increased by $4.6 million** for the six months ended June 30, 2023, compared to the same period in 2022, primarily due to higher investment and interest income from the net proceeds of the December 2022 Financing[108](index=108&type=chunk) [Liquidity and Capital Resources](index=23&type=section&id=Liquidity%20and%20Capital%20Resources) As of June 30, 2023, the company held **$203.0 million** in cash and investments, expected to fund operations through the **first half of 2025**, bolstered by **$107.6 million** from December 2022 financing - The company had **$203.0 million** in cash, cash equivalents, and short-term investments as of June 30, 2023[109](index=109&type=chunk) - Based on the current operating plan, the company expects its existing cash to be sufficient to fund operating expenses and capital expenditure requirements through the **first half of 2025**[111](index=111&type=chunk) - In December 2022, the company closed an underwritten public offering with net proceeds of **$107.6 million**, significantly strengthening its capital resources[113](index=113&type=chunk) [Item 4. Controls and Procedures](index=26&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded the company's disclosure controls and procedures were **effective** as of June 30, 2023, with **no material changes** in internal control over financial reporting during the quarter - Management, with the participation of the principal executive officer and principal financial officer, concluded that the company's disclosure controls and procedures were **effective** at a reasonable assurance level as of June 30, 2023[129](index=129&type=chunk) - There were **no changes in internal control over financial reporting** during the six months ended June 30, 2023, that have materially affected, or are reasonably likely to materially affect, internal controls[130](index=130&type=chunk) [PART II. OTHER INFORMATION](index=27&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Item 1A. Risk Factors](index=27&type=section&id=Item%201A.%20Risk%20Factors) This section refers readers to the comprehensive risk factors detailed in the company's **Annual Report on Form 10-K for the fiscal year ended December 31, 2022** - The report refers stakeholders to the detailed risk factors previously disclosed in the company's **Annual Report on Form 10-K for the fiscal year ended December 31, 2022**[132](index=132&type=chunk) [Item 6. Exhibits](index=27&type=section&id=Item%206.%20Exhibits) This section provides an **index of exhibits** filed with the **Quarterly Report on Form 10-Q**, including corporate governance documents, material agreements, and officer certifications - An **index of exhibits** filed with the **Form 10-Q** is provided, including corporate bylaws, certificates of incorporation, material agreements, and required officer certifications under the Sarbanes-Oxley Act[133](index=133&type=chunk)[134](index=134&type=chunk)

Clinical Development - STAR-0215 is in clinical development for hereditary angioedema (HAE) and aims to be a best-in-class treatment with potential administration every three or six months[56] - The Phase 1a clinical trial for STAR-0215 showed it was well-tolerated across all dose levels, with an estimated half-life of up to 117 days and sustained target engagement for at least three months[56] - The company initiated a Phase 1b/2 trial called ALPHA-STAR in February 2023, evaluating safety and quality of life in HAE patients[56] - Initial results from the Phase 1a trial are expected in the fourth quarter of 2023, with final results also anticipated in the same timeframe[56] Financial Performance - Research and development expenses decreased by 22% to $8.0 million for the three months ended March 31, 2023, down from $10.4 million in the same period in 2022[64] - The company reported an accumulated deficit of $518.8 million as of March 31, 2023, with losses from operations of $13.5 million for the three months ended March 31, 2023[59] - General and administrative expenses increased by 9% to $5.5 million for the three months ended March 31, 2023, compared to $5.0 million in the same period in 2022[64] - Total operating expenses decreased by $1.885 million to $13.493 million for the three months ended March 31, 2023, compared to $15.378 million in the same period of 2022[66] - Net loss narrowed by $4.135 million to $11.188 million for the three months ended March 31, 2023, compared to a net loss of $15.323 million in the same period of 2022[66] - Other income increased significantly to $2.305 million for the three months ended March 31, 2023, from $55 thousand in the same period of 2022, primarily due to higher yields on interest-earning assets[67] Cash and Funding - Cash, cash equivalents, and short-term investments totaled $213.3 million as of March 31, 2023, expected to fund operations through the first half of 2025[59] - The company raised an aggregate of $579.3 million through equity financings since inception, including a public offering that closed on December 19, 2022, generating net proceeds of $107.6 million[70] - Net cash used in operating activities was $13.253 million for the three months ended March 31, 2023, compared to $12.559 million in the same period of 2022[74] - Net cash provided by investing activities was $194.992 million for the three months ended March 31, 2023, primarily from maturities of short-term investments[74] - The company anticipates needing substantial additional funding to complete the development and commercialization of STAR-0215 and other product candidates[69] - The company has no committed external sources of funds and may need to seek additional financing sooner than planned due to various risks and uncertainties[69] Corporate Governance - The 2022 Inducement Stock Incentive Plan has been amended and incorporated by reference in the current report[10.1] - The principal executive officer and principal financial officer have certified compliance with the Securities Exchange Act of 1934[31.1][31.2] - The report includes certifications pursuant to the Sarbanes-Oxley Act of 2002[32.1] - Inline XBRL Instance Document is included, with embedded XBRL tags[101.INS] - The report is signed by Noah C. Clauser, Chief Financial Officer, on May 11, 2023[83]

Financial Data and Key Metrics Changes - The company reported a net loss of $13.3 million for Q4 2022, translating to $0.72 per share, and a full-year net loss of $51.8 million or $3.55 per share [29] - Cash, cash equivalents, and short-term investments increased to $226.4 million as of December 31, 2022, compared to $116.6 million as of September 30, 2022, providing a cash runway through the first half of 2025 [28][29] Business Line Data and Key Metrics Changes - The STAR-0215 program is progressing with positive results from the Phase 1a clinical trial, and the Phase 1b/2 ALPHA-STAR trial is currently underway [8][32] - The company aims for STAR-0215 to become the first-choice preventative treatment for HAE, with administration every 3 or 6 months [6][8] Market Data and Key Metrics Changes - The global HAE treatment market was over $2 billion in 2022 and is projected to grow to $4.2 billion by 2028, driven by earlier diagnoses and increased treatment options [10] - A recent market research study indicated that 100% of surveyed HAE patients expressed willingness to try a product like STAR-0215, with nearly 70% being very willing to switch to it [11][39] Company Strategy and Development Direction - The company is focused on transforming the HAE treatment paradigm with STAR-0215, which is designed for long-acting administration and aims to reduce treatment burden for patients [6][8] - The ALPHA-STAR trial is designed to assess the long-term effectiveness of STAR-0215 in preventing HAE attacks, with initial proof-of-concept results expected in mid-2024 [23][32] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of STAR-0215 to provide long-acting effective attack prevention for HAE patients, emphasizing the importance of patient feedback in guiding development [30][32] - The company is well-funded to achieve its goals, with a strong cash position supporting its operational plans through 2025 [28][32] Other Important Information - The company is exploring a 6-month dosing interval for STAR-0215, with initial results from additional cohorts expected in Q4 2023 [7][30] - The ALPHA-STAR trial is expected to include a new cohort to assess the effects of a subcutaneous dosing regimen targeting high initial concentrations of STAR-0215 [24][32] Q&A Session Summary Question: Concerns about YTE modifications and long-term side effects - Management indicated that no specific safety issues have been reported with YTE modifications in other antibodies studied, providing reassurance for STAR-0215 [36] Question: Market dynamics and competition in the HAE space - The company acknowledged the growing preventative market and expressed confidence in STAR-0215's profile to transition patients from existing treatments [39] Question: Financial outlook and operational expenses - Management provided guidance that current cash supports operations through the first half of 2025, with a gradual ramp in expenses expected as clinical activities increase [41] Question: Impact of Phase 1 study data on future development - The data from the ongoing Phase 1 study is expected to inform the strategy for STAR-0215's clinical development, particularly regarding dosing regimens [44] Question: Design considerations for the ALPHA-STAR trial - The trial was designed to eliminate the placebo group to enhance patient comfort and participation, with a focus on robust data collection [50] Question: Expected proof-of-concept data timeline - Initial proof-of-concept data from the ALPHA-STAR trial is anticipated in mid-2024, with a focus on demonstrating meaningful reductions in HAE attacks [52]

Q4/FY 2022 Financial Results and Business Update March 22, 2023 Confidential 1 Forward Looking Statements Thispresentationandvariousremarkswemakeduringthispresentationcontainforward-lookingstatementswithinthemeaningofapplicablesecuritieslawsandregulationsincluding,butnotlimitedto,statements regarding: expectationsregardingthepotentialsignificanceofthepreliminaryandinitialresultsfromthePhase1aSTAR-0215trialandtheanticipatednatureandtimingofreceiptofthedatafromthetwoadditional cohortsinsuchtrial;expectationsr ...

STAR-0215 Development and Trials - STAR-0215 is a potential best-in-class monoclonal antibody for treating hereditary angioedema (HAE), aiming for long-acting, effective attack prevention with dosing every three months or potentially less frequently[17]. - The Phase 1a clinical trial of STAR-0215 showed it was well tolerated at all dose levels (100mg, 300mg, and 600mg) with no serious adverse events and an estimated half-life of up to 117 days[19]. - Initial results from the Phase 1a trial support the potential for less frequent dosing, with evaluations for 6-month dosing expected in Q4 2023[19]. - The Phase 1b/2 trial, ALPHA-STAR, initiated in February 2023, will evaluate safety, tolerability, and quality of life in HAE patients, with initial results expected in mid-2024[20]. - STAR-0215 aims to normalize the lives of people living with HAE by providing a first-choice preventative treatment option[18]. - STAR-0215 demonstrated a half-life of approximately 117 days, supporting potential dosing every three months or less frequently[27]. - In Phase 1a clinical trials, STAR-0215 was well tolerated with no serious adverse events reported among 25 healthy subjects[27]. - The Phase 1b/2 trial, ALPHA-STAR, initiated in February 2023, will evaluate safety, tolerability, and efficacy in patients with HAE, with initial results expected in mid-2024[28]. - Preclinical studies indicated STAR-0215 has a three to four-fold longer half-life compared to lanadelumab, suggesting a significantly longer duration of action[29]. - STAR-0215's preclinical data supports its potential as a preventative therapy for HAE, with the possibility of less frequent dosing[29]. - The company plans to evaluate the potential for 6-month dosing in additional cohorts during the Phase 1a trial, with initial results expected in Q4 2023[27]. - STAR-0215 is positioned to compete directly with TAKHZYRO, a monoclonal antibody approved for HAE treatment[34]. - The company plans to develop a drug-device combination for STAR-0215, which may face regulatory hurdles that could delay clinical trials and commercialization[170]. - The success of the company’s business and future revenue generation is contingent upon the successful development and commercialization of STAR-0215, which may never occur[171]. - Clinical trials are lengthy, expensive, and uncertain, with potential for significant delays or failures impacting the development timeline of STAR-0215[178]. - The company has limited experience in designing clinical trials, which may hinder the ability to support marketing approval for STAR-0215[173]. - Adverse events or unexpected properties of STAR-0215 could delay or prevent marketing approval, impacting the company's business prospects[181]. - The company may face unforeseen events during clinical trials that could delay or prevent marketing approval for STAR-0215[182]. - The company is facing potential delays in clinical trials due to various factors, which could harm the commercial prospects for its product candidates and delay revenue generation[184]. - The company plans to conduct clinical trials outside the United States, which may be affected by global instability and other unforeseen risks[185]. - Delays in patient enrollment for clinical trials could significantly impact the timing of necessary regulatory approvals and the overall development process[187]. - STAR-0215's success will depend on its efficacy, safety, dosing frequency, and pricing compared to existing therapies[193]. - The company may face substantial competition from larger pharmaceutical and biotechnology firms, which could affect its operating results[192]. - Changes in product candidate manufacturing or formulation may lead to increased costs and delays in clinical trials[191]. - The company has limited financial and managerial resources, focusing on the development of STAR-0215, which may limit its ability to pursue other potentially profitable opportunities[202]. - The enrollment and retention of patients in clinical trials may be affected by perceptions of STAR-0215's advantages over existing therapies[197]. - The company may need to amend clinical trial protocols in response to regulatory feedback, which could result in additional costs and delays[186]. - The company has never obtained marketing approval for any product candidate, which poses a risk to future revenue generation[208]. - There is a global shortage of non-human primates for drug development, potentially increasing preclinical development costs and causing delays[206]. - The company may face delays in clinical trials if additional preclinical studies are required by the FDA or other regulatory authorities[206]. - Future research programs to identify new product candidates will require substantial resources, and failure to identify suitable compounds could harm the financial position[207]. - Approval of any marketing applications may be delayed by several years if additional studies are required by regulatory authorities[209]. - Delays in obtaining marketing approvals could prevent commercialization of STAR-0215 or future product candidates, impacting profitability[210]. - The company cannot predict the timely completion or outcome of preclinical testing, which may affect the submission of INDs or similar applications[206]. - The company may be forced to abandon development efforts for STAR-0215 or future candidates if marketing approvals are not obtained[210]. - There is uncertainty regarding the acceptance of clinical programs by the FDA or comparable foreign regulatory authorities[206]. - The company has not succeeded in demonstrating efficacy and safety in Phase 3 clinical trials for any product candidates[208]. Market Opportunity and Competition - The global market for HAE therapies is strong and growing, with an unmet medical need for potent and long-duration preventative therapies[18]. - Current FDA-approved therapies for HAE have limitations in dosing frequency and side effects, indicating a market opportunity for STAR-0215[24]. - Market research indicates strong interest from U.S. physicians and HAE patients for a product with the potential profile of STAR-0215[26]. - The estimated prevalence of Type I and Type II HAE ranges from 1 in 10,000 to 1 in 50,000, with fewer than 8,000 patients in the U.S. and 15,000 in Europe[22]. - The company is developing STAR-0215 for the treatment of HAE, competing against four FDA-approved therapies for on-demand treatment and four for long-term prevention[193]. Regulatory Environment - Regulatory processes for drug approval require substantial time and financial resources, impacting the company's operational strategy[49]. - The FDA's approval process for drugs involves multiple stages, including preclinical studies, IND submission, and clinical trials, which are critical for market entry[50][52]. - The company must submit progress reports detailing clinical trial results to the FDA at least annually, ensuring compliance with safety and efficacy standards[68]. - The recent Food and Drug Omnibus Reform Act mandates the development of diversity action plans for Phase 3 clinical trials to enhance patient population diversity[67]. - Expanded access programs allow investigational drugs to be used outside clinical trials for patients with serious conditions when no satisfactory alternatives exist[59][60]. - The company is required to comply with post-approval requirements, including potential Risk Evaluation and Mitigation Strategies (REMS) for newly approved products[52]. - Clinical trials are divided into four phases, with Phase 3 trials typically required for marketing approval, emphasizing the need for robust data collection[65][66]. - The FDA's application user fee for federal fiscal year 2023 is approximately $3.25 million, with an annual program fee exceeding $394,000 per eligible prescription product[77]. - The FDA aims to review 90% of applications for New Molecular Entities (NMEs) within ten months and 90% of priority review applications within six months[79]. - A Complete Response Letter (CRL) indicates that the application will not be approved in its current form, outlining deficiencies that may require substantial additional testing or information[84]. - The FDA may require post-approval trials and monitoring programs to assess a product's safety after commercialization, which can affect market potential and profitability[86]. - The FDA's regulations mandate that pharmaceutical products be manufactured in approved facilities and in compliance with current Good Manufacturing Practices (cGMPs)[71]. - The failure to submit clinical trial information to clinicaltrials.gov can result in civil monetary penalties of up to $10,000 for each day the violation continues[69]. - The FDA's review process includes inspections of manufacturing facilities and clinical sites to ensure compliance with regulatory standards[80][81]. - The Pediatric Research Equity Act requires sponsors to submit a pediatric study plan before submitting required data, ensuring safety and effectiveness for pediatric populations[73]. - The FDA may grant deferrals for pediatric data submission until after adult approval, based on specific criteria[75]. - The PREVENT Pandemics Act clarifies that foreign drug manufacturing establishments must register with the FDA, even if further processing occurs outside the U.S.[71]. - The FDA aims to complete its review of priority review applications within six months, compared to ten months for standard review[91]. - Accelerated approval allows drug products to be approved based on surrogate endpoints that predict clinical benefits, with post-marketing trials required[92]. - The FDORA mandates that sponsors of accelerated approval products submit progress reports on post-approval studies every six months[93]. - Regenerative advanced therapies can receive expedited development and review, with potential eligibility for priority review and accelerated approval[94]. - The Rare Pediatric Disease Priority Review Voucher program allows sponsors to receive a voucher for priority review of a subsequent application upon approval of a rare pediatric disease product[96]. - The FDA may only award a rare pediatric disease PRV if the product is designated before September 30, 2024, and approved before September 30, 2026[98]. - The Hatch-Waxman Act allows for the approval of generic drugs that are bioequivalent to previously approved drugs, with a five-year exclusivity period for new chemical entities[107]. - The BPCIA provides an abbreviated approval pathway for biosimilars, with a 12-year exclusivity period for reference products[110]. - Orphan drug designation provides advantages such as tax benefits and seven years of exclusivity for the first approved product for a rare disease[112]. - Orphan drug exclusivity does not prevent the approval of a different product for the same rare disease under certain conditions[113]. - The Court of Appeals for the 11th Circuit ruled that orphan drug exclusivity applies to the entire designated disease or condition, not just the indication or use[114]. - Pediatric exclusivity can provide an additional six months of regulatory exclusivity for drug products if pediatric data is submitted in response to FDA requests[115]. - Patent term restoration under the Hatch-Waxman Act allows for a limited extension of up to five years for patents lost during product development and FDA review[117]. - The new Clinical Trials Regulation in the EU simplifies the approval process, requiring only a single application for trials conducted in multiple Member States[119]. - The centralized procedure in the EU allows for a maximum evaluation timeframe of 210 days for marketing authorization applications, with accelerated evaluation possible in exceptional cases[126]. - Conditional marketing authorization can be granted for products intended to meet unmet medical needs, allowing market access before comprehensive clinical data is available[129]. - New chemical entities in the EU qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization[131]. - Pediatric studies conducted in accordance with a Pediatric Investigation Plan can lead to a six-month extension of protection under a supplementary protection certificate[132]. - Orphan medicinal products can receive designation if they target conditions affecting not more than five in ten thousand persons in the EU[133]. - Orphan medicinal products receive ten years of market exclusivity in the EU, with potential reduction to six years if proven sufficiently profitable[134]. - Marketing authorization for similar products can occur during the exclusivity period if they demonstrate clinical superiority or if the original product cannot meet market demand[135]. - The UK is no longer part of the EU's centralized marketing authorization process, requiring separate approvals for product candidates in the UK[138]. - The MHRA oversees medicines in Great Britain, while Northern Ireland remains under EU regulations[136]. Financial and Operational Risks - The company faces risks related to compliance with evolving privacy and data security laws, which could impact operations and financial results[164]. - The company operates in a dynamic environment with substantial risks that could affect financial performance and stock price[167]. - The company must navigate complex healthcare laws and regulations that may constrain business arrangements and impact financial outcomes[160]. - The company has limited financial and managerial resources, focusing on the development of STAR-0215, which may limit its ability to pursue other potentially profitable opportunities[202]. - The ACA and subsequent legislation have led to Medicare payment reductions of up to 4%, affecting potential revenue from product candidates[147]. - Recent legislation has delayed the 4% Medicare sequester until the end of 2024, impacting healthcare funding[148]. - Proposed regulations aim to bring transparency to pharmaceutical pricing and reduce costs under Medicare and Medicaid[151]. - The Inflation Reduction Act (IRA) requires manufacturers to negotiate prices for certain drugs with Medicare starting in 2026, impacting 10 high-cost drugs initially[154]. - Medicare out-of-pocket drug costs will be capped at an estimated $4,000 in 2024 and $2,000 in 2025, shifting some cost-sharing to drug manufacturers[155]. - The IRA imposes penalties on drug manufacturers for non-compliance with negotiated prices and requires rebates for price increases exceeding inflation[155]. - Individual states are increasingly implementing regulations to control pharmaceutical pricing, which may affect demand and pricing pressures for products[157]. - In the European Union, pricing and reimbursement schemes vary, with some countries requiring cost-effectiveness studies for drug approval[158]. - The California Consumer Privacy Act (CCPA) and the California Privacy Rights Act (CPRA) impose significant compliance requirements on businesses handling personal information[163]. - The company is developing STAR-0215 for the treatment of HAE, competing against four FDA-approved therapies for on-demand treatment and four for long-term prevention[193].

Clinical Development - STAR-0215 is in clinical development for hereditary angioedema (HAE) and aims to provide long-acting treatment with dosing every three months or longer [81]. - The Phase 1a clinical trial for STAR-0215 enrolled 24 healthy subjects, with doses of 100mg, 300mg, and 600mg administered subcutaneously [82]. - The company anticipates significant increases in research and development expenses in the upcoming quarters related to STAR-0215 [93]. - Future funding requirements will depend on various factors, including the progress and costs of clinical trials for STAR-0215 and other product candidates [124]. Financial Performance - The company reported net losses of $38.6 million for the nine months ended September 30, 2022, compared to $209.9 million for the same period in 2021 [87]. - Net loss for the three months ended September 30, 2022, was $12.0 million, compared to a net loss of $7.9 million for the same period in 2021, reflecting an increase of $4.1 million [102]. - As of September 30, 2022, the company had an accumulated deficit of $494.4 million [87]. - Other income, net increased by $595,000 to $642,000 for the nine months ended September 30, 2022, primarily due to higher yields on interest-earning assets [111]. Research and Development Expenses - Research and development expenses for STAR-0215 were $14.6 million for the nine months ended September 30, 2022, compared to $4.4 million for the same period in 2021, reflecting a significant increase [92]. - Total research and development expenses for the company were $24.7 million for the nine months ended September 30, 2022, up from $9.9 million in the prior year [92]. - Research and development expenses increased by $3.9 million to $7.7 million for the three months ended September 30, 2022, representing a 103% increase compared to the same period in 2021 [104]. - For the nine months ended September 30, 2022, research and development expenses increased by $14.8 million to $24.7 million, a 150% increase from $9.9 million in the same period in 2021 [108]. Cash and Funding - The company had $116.6 million in cash, cash equivalents, and short-term investments as of September 30, 2022 [87]. - As of September 30, 2022, the company had cash, cash equivalents, and short-term investments totaling $116.6 million, expected to support operations into mid-2024 [112]. - The company reported cash, cash equivalents, and short-term investments totaling $116.6 million as of September 30, 2022, with an additional $12.7 million raised under the Jefferies ATM Program expected to support operations into mid-2024 [123]. - The company expects to require substantial additional funding to complete the development and commercialization of STAR-0215 and support ongoing operations [87]. Operational Challenges - The company anticipates fluctuations in results of operations due to factors such as research and development progress and regulatory submission outcomes [101]. - The company may be required to delay or reduce product development efforts if additional funds are not secured in a timely manner [128]. - The company does not have any committed external sources of funds and may need to raise capital through equity offerings, debt financings, or collaborations [126]. - If additional capital is raised through equity or convertible debt, stockholders' ownership interests may be diluted [127]. - Debt financing, if available, could impose periodic payment obligations and restrictive covenants that may limit the company's operational flexibility [127]. - Collaborations or licensing arrangements may require the company to relinquish valuable rights to technologies or future revenue streams [128].

Clinical Development - STAR-0215 is in clinical development for hereditary angioedema (HAE) with a potential dosing regimen of once every three months or longer[84]. - The Phase 1a clinical trial for STAR-0215 is evaluating safety and pharmacokinetics with preliminary results anticipated by year-end 2022[85]. - The company plans to initiate a Phase 1b/2 trial in participants with HAE in 2023, assuming positive data from the Phase 1a trial[85]. Financial Performance - The company reported net losses of $26.6 million for the six months ended June 30, 2022, compared to $177.6 million for the same period in 2021[91]. - Net loss for the six months ended June 30, 2022, was $26.6 million, a decrease of $150.9 million from a net loss of $177.5 million for the same period in 2021[113]. - Other income, net increased by $234,000 to $253,000 for the six months ended June 30, 2022, from $19,000 for the same period in 2021, mainly due to higher yields on interest-earning assets[115]. Research and Development Expenses - Research and development expenses for STAR-0215 were $10.1 million for the six months ended June 30, 2022, significantly up from $2.9 million in the same period of 2021[96]. - Total research and development expenses for the six months ended June 30, 2022, were $17.0 million, compared to $6.1 million in the same period of 2021[96]. - Research and development expenses increased by 180% to $17.0 million for the six months ended June 30, 2022, compared to $6.1 million for the same period in 2021[112]. - Research and development expenses for the three months ended June 30, 2022, increased by 90% to $6.6 million from $3.5 million for the same period in 2021[108]. Cash and Investments - The company had $102.5 million in cash, cash equivalents, and short-term investments as of June 30, 2022, expected to support operations through 2023[91]. - Cash, cash equivalents, and short-term investments totaled $102.5 million as of June 30, 2022, expected to support operating expenses through 2023[116]. - As of June 30, 2022, the company had available cash, cash equivalents, and short-term investments of $102.5 million, expected to support operating expenses and capital expenditures through 2023[126]. Operating Expenses - General and administrative expenses rose by 43% to $9.9 million for the six months ended June 30, 2022, from $6.9 million for the same period in 2021[114]. - The total operating expenses for the six months ended June 30, 2022, were $26.8 million, a decrease of $150.7 million compared to $177.6 million for the same period in 2021, primarily due to the absence of acquired in-process research and development expenses[113]. - General and administrative expenses for the three months ended June 30, 2022, increased by 21% to $4.8 million from $4.0 million for the same period in 2021[109]. Funding and Capital Requirements - The company anticipates needing substantial additional funding to complete the development and commercialization of STAR-0215 and future product candidates[117]. - The company raised an aggregate of $426.0 million through various financing activities since inception, with net proceeds of approximately $104.3 million from the February 2021 Financing[116][118]. - The company may need to seek additional funds sooner than planned due to uncertainties in research, development, and commercialization of biotechnology products[127]. - Future funding requirements will depend on various factors, including clinical trial progress and regulatory approval outcomes[127]. - The company does not have any committed external source of funds and may rely on equity offerings, debt financings, and collaborations for financing[129]. - If additional capital is raised through equity or convertible debt, stockholders' ownership interests may be diluted[129]. - The company may have to relinquish valuable rights to technologies or future revenue streams if funds are raised through collaborations or licensing arrangements[130]. Impact of COVID-19 - The impact of the COVID-19 pandemic on operations and business prospects remains a concern for future funding and development efforts[127].

Financial Performance - The company reported net losses of $15.3 million for Q1 2022, compared to $170.1 million for Q1 2021, which included $164.6 million in in-process research and development expenses [91]. - Total operating expenses decreased significantly from $170.1 million in Q1 2021 to $15.4 million in Q1 2022, primarily due to the absence of acquired in-process research and development expenses [111]. - The net loss for the three months ended March 31, 2022, was $15.3 million, a reduction of $154.8 million compared to a net loss of $170.1 million in the same period of 2021 [111]. - Research and development expenses increased by 299% to $10.4 million for the three months ended March 31, 2022, compared to $2.6 million for the same period in 2021 [108]. - General and administrative expenses rose by 74% to $5.0 million for the three months ended March 31, 2022, up from $2.9 million in the prior year [109]. - Net cash used in operating activities was $12.6 million for the three months ended March 31, 2022, compared to $8.7 million for the same period in 2021 [118]. Cash and Funding - As of March 31, 2022, the company had an accumulated deficit of $471.1 million and $112.8 million in cash, cash equivalents, and short-term investments [91]. - Cash, cash equivalents, and short-term investments totaled $112.8 million as of March 31, 2022, sufficient to support operations through 2023 [112]. - The company raised an aggregate of $426.0 million through various financing activities from inception through March 31, 2022 [112]. - The company anticipates needing substantial additional funding to complete the development and commercialization of STAR-0215 and support ongoing operations [91]. - The company expects to incur additional funding needs to support the development and commercialization of STAR-0215 and other future product candidates [113]. - The company anticipates needing additional financing to achieve business objectives, as substantial product revenues are not expected for several years [124]. - Future funding requirements will depend on various factors, including the progress of clinical trials for STAR-0215 and other product candidates [122]. - The company has no committed external source of funds and may need to raise capital through equity offerings or debt financing, which could dilute stockholder ownership [125]. - The company may have to relinquish rights to technologies or revenue streams if it raises funds through collaborations or licensing arrangements [126]. Product Development - The lead product candidate, STAR-0215, is in preclinical development for hereditary angioedema (HAE) and is expected to enter a Phase 1a clinical trial in mid-2022, with initial results anticipated by year-end 2022 [83]. - STAR-0215 has shown to be approximately 10-fold more potent than lanadelumab in inhibiting bradykinin production, with a projected half-life of approximately 34 days compared to lanadelumab's 10 days [84]. - The company plans to initiate a Phase 1b/2 trial in HAE patients in 2023, assuming positive data from the Phase 1a trial [83]. - The acquisition of Quellis Biosciences in January 2021 provided the STAR-0215 program, with gross proceeds of approximately $110.0 million from a private placement in February 2021 [82]. - The global market for HAE therapy is strong and growing, indicating a significant unmet medical need that STAR-0215 aims to address [83]. - The company anticipates significant research and development expenses in future periods related to the development of STAR-0215, with costs expected to be higher than prior year periods [96]. Operational Considerations - The impact of the COVID-19 pandemic on operations and business prospects remains a consideration [123]. - The company has not experienced changes in internal control over financial reporting that materially affect its operations as of March 31, 2022 [133]. - Management's disclosure controls and procedures were deemed effective at the reasonable assurance level as of March 31, 2022 [132]. - Total contractual cash obligations amounted to $2.39 million, with $1.63 million related to operating lease obligations and $0.77 million under vendor agreements contingent on clinical milestones [128].